Salud financiera de hoja de balance de Immunovant
Salud financiera controles de criterios 6/6
Immunovant tiene un patrimonio de los accionistas total de $679.3M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $711.4M y $32.1M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$690.94m |
| Patrimonio | US$679.34m |
| Total pasivo | US$32.10m |
| Activos totales | US$711.45m |
Actualizaciones recientes sobre salud financiera
We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Apr 19
We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Sep 28Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation
Jun 14Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans
Mar 08We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate
Nov 06We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate
Aug 06Recent updates
We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Apr 19Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)
Apr 04Immunovant: An Intriguing And Developing Story
Jan 25Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate
Jan 12We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Sep 28Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation
Jun 14Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans
Mar 08We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate
Nov 06Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset
Oct 17Immunovant stock down on raising $75M though equity capital
Oct 04We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate
Aug 06Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation
Apr 06We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Jun 20Immunovant EPS beats by $0.04
Jun 01argenx rise even as Immunovant pauses the trial for anti-FcRn therapy
Feb 03Immunovant slips 7% on voluntary hold of IMVT-1401 dosing
Feb 02Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management
Jan 14Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?
Dec 30Immunovant (IMVT) Investor Presentation - Slideshow
Nov 16Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($710.8M) de IMVT superan a sus pasivos a corto plazo ($32.1M).
Pasivo a largo plazo: IMVT no tiene pasivos a largo plazo.
Historial y análisis de deuda-patrimonio
Nivel de deuda: IMVT está libre de deudas.
Reducción de la deuda: IMVT no tenía deudas hace 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: IMVT tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.
Pronóstico de cash runway: IMVT dispone de suficiente cash runway para 2.7 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 27.8% cada año.